Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-05-20 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2023 annual equity distribution (dividend) plan by Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the dividend amount, payment dates, tax withholding policies, and the record and ex-dividend dates. It references the shareholders' meeting approval and provides contact information. The content is focused on dividend distribution specifics rather than financial results or reports. The document length is short (1280 characters) and it is clearly an announcement of dividend payment details, matching the definition of a Notice of Dividend Amount (DIV).
2024-05-20 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the convening and attendance of the 2024 AGM, including voting results on various proposals such as the 2023 annual report, financial reports, profit distribution, appointment of auditors, and other corporate governance matters. The document includes voting outcomes and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements but rather the resolutions passed at the AGM. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting. The document length (7589 characters) and content confirm it is not a full report but a voting results announcement from the AGM.
2024-04-23 Chinese
关于二甲双胍恩格列净片（Ⅲ）获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval and issuance of a drug registration certificate by the National Medical Products Administration (NMPA) for a specific pharmaceutical product. It details the drug's specifications, regulatory approval, and potential impact on the company. The document is short (1302 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-23 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2023年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the validity of the resolutions passed. It does not contain the actual AGM materials or presentations but rather a legal opinion on the AGM process and results. The document length is 3473 characters, which is relatively short and consistent with a legal opinion or meeting summary rather than a full report. Therefore, this document fits best under the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related official documents about the AGM proceedings.
2024-04-23 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 First Quarter Report" of Jiangsu Deyuan Pharmaceutical Co., Ltd. It contains detailed financial data for the first quarter of 2024, including balance sheet, income statement, cash flow statement, and explanations of significant changes. It also includes information about shareholders, major shareholders, and corporate governance matters. The document explicitly states it is a quarterly report (第一季度报告) and includes comprehensive financial data and management discussion. It is not an announcement or a brief summary but a full quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-23 Chinese
第四届监事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the review and approval of the company's 2024 first quarter report. It states that the Supervisory Board has reviewed the quarterly report prepared by the Board of Directors and confirms its compliance and accuracy. The document does not contain the actual financial statements or detailed financial data of the quarterly report itself but rather the meeting resolution approving that report. The document length is short (1039 characters) and it references the quarterly report being published on the Beijing Stock Exchange website with a separate announcement number (2024-044). This fits the pattern of a meeting resolution or announcement related to management or board decisions rather than the report itself. Therefore, the best classification is Board/Management Information (MANG), as it announces a board-level resolution and approval of a financial report rather than the report itself or a full interim report.
2024-04-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.